

A simplified 4-site economical intradermal post-exposure rabies vaccine regimen : a randomised controlled comparison with standard methods

Warrell, Mary J; Riddell, Anna; Yu, Ly-Mee; Phipps, Judith; Diggle, Linda; Bourhy, Hervé; Deeks, Jonathan J; Fooks, Anthony R; Audry, Laurent; Brookes, Sharon M; Meslin, François-Xavier; Moxon, Richard; Pollard, Andrew J; Warrell, David A

DOI:

[10.1371/journal.pntd.0000224](https://doi.org/10.1371/journal.pntd.0000224)

License:

Creative Commons: Attribution (CC BY)

Document Version

Publisher's PDF, also known as Version of record

Citation for published version (Harvard):

Warrell, MJ, Riddell, A, Yu, L-M, Phipps, J, Diggle, L, Bourhy, H, Deeks, JJ, Fooks, AR, Audry, L, Brookes, SM, Meslin, F-X, Moxon, R, Pollard, AJ & Warrell, DA 2008, 'A simplified 4-site economical intradermal post-exposure rabies vaccine regimen : a randomised controlled comparison with standard methods', *PLoS Neglected Tropical Diseases*, vol. 2, no. 4, e224. <https://doi.org/10.1371/journal.pntd.0000224>

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:

Eligibility for repository : checked 11/08/2014

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

A Simplified 4-Site Economical Intradermal Post-Exposure Rabies Vaccine Regimen: A Randomised Controlled Comparison with Standard Methods

Mary J. Warrell¹, Anna Riddell¹, Ly-Mee Yu², Judith Phipps¹, Linda Diggle¹, Hervé Bourhy³, Jonathan J. Deeks², Anthony R. Fooks⁴, Laurent Audry³, Sharon M. Brookes⁴, François-Xavier Meslin⁵, Richard Moxon¹, Andrew J. Pollard¹, David A. Warrell^{1*}

1 The Oxford Vaccine Group, Centre for Clinical Vaccinology & Tropical Medicine University of Oxford, Churchill Hospital, Oxford, United Kingdom, **2** Centre for Statistics in Medicine, University of Oxford, Oxford, United Kingdom, **3** UPRE Lyssavirus Dynamics and Host Adaptation, WHO Collaborating Centre for Reference and Research on Rabies, Institut Pasteur, Paris, France, **4** Rabies and Wildlife Zoonoses Group, WHO Collaborating Centre for the Characterization of Rabies and Rabies-Related Viruses, Veterinary Laboratories Agency, Weybridge, United Kingdom, **5** Zoonoses and VPH, Department of Food Safety, Zoonoses and Foodborne Diseases, World Health Organization, Geneva, Switzerland

Abstract

Background: The need for economical rabies post-exposure prophylaxis (PEP) is increasing in developing countries. Implementation of the two currently approved economical intradermal (ID) vaccine regimens is restricted due to confusion over different vaccines, regimens and dosages, lack of confidence in intradermal technique, and pharmaceutical regulations. We therefore compared a simplified 4-site economical PEP regimen with standard methods.

Methods: Two hundred and fifty-four volunteers were randomly allocated to a single blind controlled trial. Each received purified vero cell rabies vaccine by one of four PEP regimens: the currently accepted 2-site ID; the 8-site regimen using 0.05 ml per ID site; a new 4-site ID regimen (on day 0, approximately 0.1 ml at 4 ID sites, using the whole 0.5 ml ampoule of vaccine; on day 7, 0.1 ml ID at 2 sites and at one site on days 28 and 90); or the standard 5-dose intramuscular regimen. All ID regimens required the same total amount of vaccine, 60% less than the intramuscular method. Neutralising antibody responses were measured five times over a year in 229 people, for whom complete data were available.

Findings: All ID regimens showed similar immunogenicity. The intramuscular regimen gave the lowest geometric mean antibody titres. Using the rapid fluorescent focus inhibition test, some sera had unexpectedly high antibody levels that were not attributable to previous vaccination. The results were confirmed using the fluorescent antibody virus neutralisation method.

Conclusions: This 4-site PEP regimen proved as immunogenic as current regimens, and has the advantages of requiring fewer clinic visits, being more practicable, and having a wider margin of safety, especially in inexperienced hands, than the 2-site regimen. It is more convenient than the 8-site method, and can be used economically with vaccines formulated in 1.0 or 0.5 ml ampoules. The 4-site regimen now meets all requirements of immunogenicity for PEP and can be introduced without further studies.

Trial Registration: Controlled-Trials.com ISRCTN 30087513

Citation: Warrell MJ, Riddell A, Yu L-M, Phipps J, Diggle L, et al. (2008) A Simplified 4-Site Economical Intradermal Post-Exposure Rabies Vaccine Regimen: A Randomised Controlled Comparison with Standard Methods. *PLoS Negl Trop Dis* 2(4): e224. doi:10.1371/journal.pntd.0000224

Editor: Peter J. Hotez, The George Washington University, United States of America

Received: December 4, 2007; **Accepted:** March 14, 2008; **Published:** April 23, 2008

Copyright: © 2008 Warrell et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The study was funded by the Wellcome Trust (Project Grant 065947) and the University of Oxford Medical Research Fund (Bridging support Grant MRF/1808). The World Health Organization contributed to the cost of serological testing. ARF and SMB were financially supported by a grant from the UK Department for Environment, Food and Rural affairs (Defra) grant SEV3500. AJP is a Jenner Institute Investigator. The funders had no role in the study design, data collection and analysis, decision to publish or manuscript preparation.

Competing Interests: AJP acts as chief investigator for clinical trials conducted on behalf of Oxford University, sponsored by vaccine manufacturers (Novartis Vaccines, GlaxoSmithKline, Sanofi-Aventis, Sanofi-Pasteur MSD, and Wyeth Vaccines). AJP and LD have received assistance from vaccine manufacturers to attend scientific meetings. Industry-sourced honoraria for lecturing or writing are paid directly to an independent charity or an educational/administrative fund held by the Department of Paediatrics, University of Oxford. RM is a member of the SAB for Novartis. Sanofi Pasteur had no role in the trial design, the conduct of the study or the publication. MJW, AR, ARF, JJP, SMB, HB, LA, JD, F-XM, and DAW have no conflicts of interest.

* E-mail: mary.warrell@ndm.ox.ac.uk

Introduction

Rabies is a neglected disease affecting particularly tropical developing countries [1]. Estimates of the Global use of rabies post-exposure prophylaxis (PEP) are rising. In China, it was 8

million in 2005 [2], yet rabies currently kills more people than any other infectious disease there. Rabies deaths are underreported and misdiagnosed, for example as cerebral malaria [3]. As the obsolete nervous tissue-based rabies vaccines are replaced by expensive tissue culture vaccines, there is increasing need to

Author Summary

All human deaths from rabies result from failure to give adequate prophylaxis. After a rabid animal bite, immediate wound cleaning, rabies vaccine and immunoglobulin injections effectively prevent fatal infection. Immunoglobulin is very rarely available in developing countries, where prevention relies on efficacious vaccine. WHO approved vaccines are prohibitively expensive, but 2 economical regimens (injecting small amounts of vaccine intradermally, into the skin, at 2 or 8 sites on the first day of the course) have been used for many years in a few places. Practical or perceived difficulties have restricted widespread uptake of economical methods. These could largely be overcome by introducing a new, simpler regimen, involving 4 site injections on the first day. We vaccinated volunteers to compare the antibody levels induced by the 4-site intradermal regimen with those induced by the current 2-site and 8-site regimens and the “gold standard” intramuscular regimen favoured internationally. All the economical intradermal regimens were at least as immunogenic as the intramuscular method. The results provide sufficient evidence that the 4-site regimen meets the criteria necessary for its recommendation for use wherever the cost of vaccine is prohibitive and especially where 2 or more patients are treated on the same day.

reduce the cost of post-exposure prophylaxis. In Africa, the average cost of a standard intramuscular (IM) course of vaccine is \$39.6, equivalent to 50 days wages [1]. There is a shortage of affordable rabies vaccines of reliable quality in the developing world [4].

Economical PEP regimens employ multiple site intradermal (ID) injections, saving 60% of the vaccine used in the standard IM method (Table 1). Increasing the number of sites of injection is designed to stimulate several different groups of lymph nodes to initiate antibody production. Two economical regimens are now recommended [5], an 8-site [6] and a 2-site [7] method (Table 1). The urgency of PEP demands a rapid induction of neutralising antibody using minimal amounts of vaccine in all recipients including the ~3% of the population who are ‘low responders’ [8] and the many others whose immune response is impaired [9–12].

The original IM PEP vaccine regimen is the most widely used globally. In Asia only 3% of tissue culture rabies vaccine treatments use economical ID regimens [1], and they are rarely used in Africa. The reasons are misgivings about reducing the vaccine dosage in prevention of a fatal disease [13], confusion over regimens, and the competence of staff giving ID inoculation. Economical regimens require sharing of ampoules between

patients, but rabies vaccines have no added preservative and so the reconstituted ampoule of vaccine should be used within a day. The use of economical regimens is therefore mainly confined to large treatment centres, yet 90% of rabies deaths occur in rural areas [4].

Evidence to date indicates that the 8-site regimen is more immunogenic than the 2-site regimen [14,15]. However the 8-site method is not economical when used with one of the two major vaccines, purified vero cell rabies vaccine (PVRV) (Verorab™ Sanofi Pasteur), because this vaccine is relatively concentrated: an IM dose is 0.5 ml, in contrast to the equivalent 1 ml dose of the other widely used vaccine, purified chick embryo cell vaccine (PCECV) (Rabipur™; Novartis) [15]. Although the 8-site regimen has some advantages and was recommended by some authorities for use when rabies immunoglobulin (RIG) was not available [15], the 2-site regimen is more acceptable and convenient. The total dose of vaccine should be the same with the two regimens. The only difference between the two schedules is that with the 8-site a large dose of vaccine is given on the first day, whereas with the 2-site regimen this is divided between days 0 and 3, entailing an extra treatment visit [14]. Ambrozaitis et al. [16] demonstrated that the 4-site regimen was apparently immunogenic with both PVRV and PCEC vaccines, but there was no comparison with any current PEP method and historical controls are unreliable.

For all these reasons, a single, simple, acceptable, immunogenic and economical PEP regimen is needed, suitable for use with all vaccines fulfilling WHO requirements. We tested a 4-site PEP regimen which allows the 8-site regimen principle to be used economically with PVRV. We also investigated whether injecting the same amount of vaccine between 4 instead of 8 sites affected immunogenicity. The new 4-site regimen and the currently used ID regimens were compared with the standard IM method in a single blind, randomised, controlled trial.

Methods

The CONSORT checklist for this study is available in Supporting Information as Checklist S1.

Participants

Healthy volunteers were recruited in Oxford and Bristol UK, between June 2002 and April 2005. The exclusion criteria were: previous rabies vaccine treatment; pregnancy; a recent blood transfusion; taking immunosuppressive drugs; receiving another killed vaccine or chloroquine treatment [17] within 2 weeks, or any live virus vaccine within 3 weeks of a rabies vaccine dose. The Oxfordshire Clinical Research Ethics Committee approved the project (ref. C01.078), conducted in accordance with GCP regulations (EU Directive 2001/20/EC).

Table 1. Vaccine Regimens Showing Number of Sites of Injection.

| Regimen | Day 0 | Day 3 | Day 7 | Day 14 | Day 28 | Day 90 | Total Ampoules of Vaccine |
|--------------|-------------|-------|-------|--------|--------|--------|---------------------------|
| A 4-site ID | 4 (0.5 ml)* | | 2 | | 1 | 1 | 1.8 (0.9 ml) |
| B 8-site† ID | 8 (0.5 ml)* | | 4 | | 1 | 1 | 1.6 (0.8 ml) |
| D 2-site ID | 2 (0.2 ml) | 2 | 2 | | 1 | 1 | 1.6 (0.8 ml) |
| E IM | 1 (0.5 ml) | 1 | 1 | 1 | 1 | | 5 |

*Whole ampoule of vaccine divided between sites.

†For the 8-site regimen, the intradermal (ID) dose is 0.05 ml per site. All other ID doses are 0.1 ml per site. ID injection sites over deltoids for 1 or 2 sites. 4 sites are deltoids and thighs.

8 sites are deltoids, thighs, suprascapular, and lower anterior abdominal wall areas. Intramuscular (IM) injection into the left deltoid.

doi:10.1371/journal.pntd.0000224.t001

Randomisation

Each participant was allocated to one of four rabies PEP regimens according to a computer generated list with fixed blocks of 12. Group A received the 4-site regimen; group B, the 8-site regimen; group D, the 2-site regimen and group E, the IM regimen. Allocations were concealed in opaque serially numbered sealed envelopes, opened once written informed consent had been obtained. All laboratory staff were blinded to the treatment allocation.

Vaccine and regimens

The vaccine used was PVRV, (Verorab™ Sanofi Pasteur) Lot no. XO291-1 potency 5.3 IU/dose in 165 subjects, and Lot no. U0271 potency 8.4 IU/dose in 64 subjects. The Medicines and Healthcare products Regulatory Agency granted exemption from a licence.

The 2-site and IM regimens were according to standard methods (Table 1) [15]. For the 4-site regimen, on day 0 the entire contents of the 0.5 ml PVRV vial are injected ID, divided between 4 sites over the deltoids and thighs (approximately 0.1 ml per site).

On day 7, 0.1 ml is injected ID at 2 sites (deltoids). Single site injections are given on days 28 and 90. The 8-site regimen is the exact equivalent of the current 8-site method [6,15], using a vaccine containing 0.5 ml/ampoule. The entire contents of the vial are divided between 8 ID sites on day 0: (deltoids, thighs, suprascapular, lower anterior abdominal wall). The dose per site is approximately 0.05 ml. All the ID regimens use the same total amount of vaccine. There is a little inevitable wastage in syringes. Opened ampoules were refrigerated and used or discarded within 8 hours. See Table 1 for the timing, doses, routes and sites of inoculation of all the regimens.

Serology

Blood samples were taken at days 0, 7, 14, 90 and 1 year. Serum aliquots were coded, stored at -70°C and assayed blind. Neutralising antibody levels were measured by an adaptation of the rapid fluorescent focus inhibition test (RFFIT) for 96 well plates [18,19], at the Institut Pasteur, Paris. Briefly, a constant dose of challenge virus standard (CVS) is incubated with diluted test sera. An in-house reference serum (SHR2 31/03/06 = 22 IU/ml), is calibrated against an international standard (RAI = 30 IU/ml). Serum/virus mixtures are incubated, and BSR cells (a clone of BHK-21 cells) were added. After 24 hours incubation, the monolayer is acetone-fixed and stained with a fluorescent anti-nucleocapsid antibody (Chemicon). The result in IU/ml was the mean of independent duplicate tests.

Selected sera were also assessed using the fluorescent antibody virus neutralisation (FAVN) assay at the Veterinary Laboratories Agency, Weybridge [20,21]. This test is the same in principle as the RFFIT, using the same challenge virus. The FAVN and RFFIT vary in that they use a different dilution series (3 fold versus 5 fold); the FAVN runs samples in quadruplicate; BHK-21 cells (ATCC, USA) are used, and the internal serum standard is the WHO human positive control (NIBSC, UK). The antibody titre is based on 100% virus neutralisation for the FAVN and 50% reduction of fluorescent foci in the RFFIT.

Protocol deviations were not permitted on days 7 and 14, but flexibility was allowed if necessary: on day 28 ± 1 day; on day 90 - 7 to +10 days, and at one year -2 weeks to +4 weeks. All records were kept in strict confidence. Volunteers kept a health record diary for a week after each vaccine dose.

Statistical methods

The aim was to demonstrate that the 4-site test regimen was at least as immunogenic as the standard regimens. The primary outcome is the proportion of participants reaching the WHO

criterion for post-exposure regimens: a minimum neutralising antibody level of 0.5 IU/ml by day 14. The failure rate for the current regimen in meeting this threshold is less than one in 1000. At this rate, the expected number of failures in the control group is likely to be zero. The sample size calculation was based on the assumption that the new regimen was just as effective (i.e. rate of less than 1 in 1000) and was computed by simulation method using exact methods for estimating the confidence interval (CI) for the difference.

The initial protocol envisaged the recruitment of 75 participants per group to make 5 comparisons over 7 regimens expecting zero events to be observed, giving 90% power to show that the difference in failure rates was at most 6.2% (adjusting for pre-planned multiple comparisons). Because the trial failed to recruit at an adequate rate, the revised sample size of 55 participants per group (Protocol S1) was calculated for a total of 6 comparisons among four groups giving 90% power to show that the difference in failure rates was at most 9% by day 14.

Proportions and 95% CI for the difference in proportions were calculated using the method based on Wilson's score [22]. Agreement between the results of the two antibody tests was assessed by the Bland-Altman method [23]. Titre concentrations were log transformed and groups were compared using analysis of variance. Results were deemed statistically significant at $P < 0.05$. Fisher's exact test was used to compare side effects between groups. Post-hoc pairwise comparisons were also carried out on any local reactions (redness, swelling hardness, or tenderness/pain) and on any local or generalised signs or symptoms. P-values were adjusted if multiple comparisons were performed.

Results

Participant flow

Two hundred and fifty four subjects were recruited. Data from 229 were complete up to day 90, and used in the final analysis. Twenty five were excluded, usually because they failed to keep appointments (for details see Figure 1). Three sera taken on day 14 were lost during storage.

Subjects were aged between 18 and 50 years. Ages and sex ratios were similar between the groups (Table 2).

Side effects

One person withdrew within the first week because of transient arthralgia, possibly related to the vaccine.

Local reactions to the vaccine observed by 229 volunteers are shown in Table 3. Redness (erythema), swelling (inflammation) and hardness (induration) were more frequent in all ID groups than in the IM group (E) ($P < 0.0001$). The incidence of local tenderness or pain was similar in all groups. Itchiness and local lymphadenopathy (tenderness at regional lymph nodes) was not solicited, but was volunteered more often in the ID groups ($P < 0.0001$).

Volunteers were asked to report any generalised symptoms, whether or not listed in their reaction diary. Some were attributable to causes unrelated to vaccination. The incidence of each of the generalised symptoms was lower with the IM regimen but this only reached significance when compared with all three ID groups together ($P < 0.001$) (Table 4).

RFFIT serology results

The lower limit of detection of antibody was 0.06 IU/ml, while the threshold for a positive result, was 0.3 IU/ml, as naïve sera can range between 0 and 0.3 IU/ml.

Two sera gave pre-vaccination results above this threshold (the means of two tests were 0.38 IU/ml and 0.46 IU/ml). These subjects denied previous rabies immunisation and subsequent

FLOW DIAGRAM OF SUBJECTS RECRUITED TO RABIES VACCINE STUDY




Figure 1. Flow diagram of subjects recruited to rabies vaccine study. Group A received the 4-site regimen; group B, the 8-site regimen; group D, the 2-site regimen and group E, the IM regimen. doi:10.1371/journal.pntd.0000224.g001

titres did not suggest a secondary immune response, but they were excluded from the analysis. Data for the remaining 227 people were analysed. Undetectable titres were assigned the value of 0.02.

Geometric mean titres (GMTs) on day 7 for the 4 treatment groups (Table 5, Figure 2), showed that group E (IM) had a lower GMT than group D (2-site) ($P < 0.001$) and group B (8-site) ($P = 0.01$). Group A (4-site) was lower than group D ($P = 0.01$). The percentage of people with detectable antibody > 0.3 IU/ml was 60%, 77.6%, 86.2% and 62.5% for groups A, B, D and E respectively. The day 7 results were no different with the two batches of vaccine (data not shown).

On day 14 all subjects had antibody levels > 0.5 IU/ml (Table 5, Figure 2). The 95% confidence intervals for the differences in proportions between any two regimens indicated that differences could at most be between 6% and 7% (Figure 3). The only significant difference between the GMTs is that Group E (IM) was lower than group D (2-site) ($P = 0.04$).

Table 2. Demographic Characteristics.

| | Group A 4-site (n = 55) | Group B 8-site (n = 60) | Group D 2-site (n = 58) | Group E IM (n = 56) |
|---------------------|--|--|--|--------------------------------|
| Sex | | | | |
| No. Females (%) | 34 (61.8) | 40 (66.7) | 46 (79.3) | 32 (57.1) |
| No. Males (%) | 21 (38.2) | 20 (33.3) | 12 (20.7) | 24 (42.9) |
| Ages (years) | | | | |
| Mean (SD) | 28.0 (9.2) | 28.8 (9.6) | 26.5 (6.9) | 31.6 (10.0) |
| Range | 18.3–50.8 | 19.0–49.4 | 18.1–44.4 | 18.1–50.7 |

doi:10.1371/journal.pntd.0000224.t002

On day 90, GMTs were similar (Table 5, Figure 2). At 1 year all ID recipients had detectable antibody, but two people in group E (IM) had < 0.3 IU/ml. Eight had levels between 0.3 and 0.5 IU/ml: 2 in group A, 2 in group B and 6 in group E. All the ID regimens induced more persistent antibody than the IM group ($P < 0.001$ for groups B and D, $P < 0.02$ for A). The 2-site (D) GMT was greater than the 4-site (A) ($P < 0.04$).

Before the serological data were decoded, some unusual results were identified. Antibody levels were unexpectedly high on days 7 and 14, compared with other clinical trials [6,7,16]. Two subjects were excluded because they had pre-vaccination antibody levels above the 0.3 IU/ml threshold. Two people had antibody levels > 3000 IU/ml on day 14 (both of them later proved to be in group D). The next highest were seven subjects with levels between 1000 and 1500 IU/ml. The other results for these people were well within the range of the rest. After decoding, none of the high results was found to be among group A subjects. They were individual high titres, without any suggestion of an anamnestic response. To confirm the results of the trial, 224 (of the original 229) day 7 samples available, and a few others (see below) were tested blind in another laboratory which uses the FAVN method.

FAVN serology results and comparison with RFFIT

The FAVN lower limit of detection of antibody was 0.05 IU/ml. The threshold for a positive result is > 0.13 as naïve sera can range up to 0.1 IU/ml.

The day 7 results for 224 subjects, including the 2 excluded because of high initial RFFIT titres, showed GMTs between 1.044 IU/ml for group D (2-site) and 0.573 IU/ml for E (IM) ($P < 0.01$) (Table 6, Figure 4). There were no other significant differences and GMTs were in the same order as the RFFIT results for all 4 treatment groups. The percentage of people with detectable antibody, > 0.13 IU/ml, was 96.3 %, 93.0%, 96.6 % and 87.3 % for groups A, B, D and E respectively.

Table 3. Local Reactions.

| Reaction | Group A 4-site (n = 55) | Group B 8-site (n = 60) | Group D 2-site (n = 58) | Group E IM (n = 56) | P-value |
|---------------------|-------------------------|-------------------------|-------------------------|---------------------|----------|
| Redness | 53 (96.4%) | 58 (96.7%) | 54 (93.1%) | 14 (25.0%) | <0.0001 |
| Swelling | 42 (76.4%) | 48 (80.0%) | 46 (79.3%) | 8 (14.3%) | <0.0001 |
| Hardness | 41 (74.6%) | 44 (73.3%) | 38 (65.5%) | 9 (16.1%) | <0.0001 |
| Tenderness/ Pain | 39 (70.9%) | 35 (58.3%) | 41 (70.7%) | 31 (55.4%) | 0.2 |
| Any above reactions | 53 (96.4%) | 58 (96.7%) | 54 (93.1%) | 33 (58.9%) | <0.0001* |
| Itchiness | 26 (47.3%) | 29 (48.3%) | 28 (48.3%) | 2 (3.6%) | <0.0001 |
| Lymphadenopathy | 5 (9.1%) | 15 (25.0%) | 8 (13.8%) | 0 (0%) | <0.0001 |

*Post hoc test: A vs E, P<0.0001; B vs E, P<0.001; D vs E, P<0.001.
doi:10.1371/journal.pntd.0000224.t003

Table 4. Generalised Symptoms Reported and the % Possibly or Probably Related to Vaccine.

| Reaction | Group A 4-site | Group B 8-site | Group D 2-site | Group E IM | P-value |
|--|----------------|----------------|----------------|-------------|----------|
| Shivery | 7/9 (78%) | 5/11 (45%) | 4/6 (67%) | 3/6 (50%) | 0.5 |
| Vomited | 2/2 (100%) | 0/1 (0%) | 0/3 (0%) | 0/2 (0%) | 0.07 |
| Musc/joint | 11/15 (73%) | 13/25 (52%) | 7/11 (64%) | 4/12 (31%) | 0.2 |
| Headache | 25/32 (78%) | 23/39 (59%) | 21/32 (66%) | 9/22 (41%) | 0.05 |
| Diarrhoea | 5/6 (83%) | 2/4 (50%) | 1/3 (33%) | 0/1 (0%) | 0.3 |
| Rash | 4/4 (100%) | 4/4 (100%) | 2/3 (67%) | 1/1 (100%) | 0.3 |
| Any generalised symptoms | 33/34 (97%) | 31/34 (91%) | 26/28 (93%) | 13/14 (93%) | 0.8 |
| Any local or generalised signs or symptoms | 55 (100%) | 58 (96.7%) | 54 (93.1%) | 35 (62.5%) | <0.0001* |

*Post hoc test: A vs E, P<0.0001; B vs E, P<0.001; D vs E, P<0.001
doi:10.1371/journal.pntd.0000224.t004

Table 5. RFFIT Serology Results.

| | Group A 4-site | Group B 8-site | Group D 2-site | Group E IM |
|---------------|--------------------|--------------------|--------------------|--------------------|
| Day 7 | | | | |
| N | 55 | 58 | 58 | 56 |
| GMT* | 0.44 | 0.67 | 0.88 | 0.36 |
| Range | (0.02 to 6.89) | (0.06 to 6.21) | (0.2 to 8.39) | (0.02 to 2.79) |
| 95% CI | (0.31 to 0.61) | (0.53 to 0.86) | (0.69 to 1.11) | (0.26 to 0.50) |
| Day 14 | | | | |
| N | 54 | 58 | 58 | 54 |
| GMT* | 334.66 | 308.11 | 363.66 | 228.45 |
| Range | (43.7 to 811.5) | (24.3 to 1459.0) | (60.9 to 3711.5) | (5.5 to 1282.6) |
| 95% CI | (278.68 to 401.79) | (248.66 to 381.77) | (299.16 to 442.08) | (161.99 to 322.18) |
| Day 90 | | | | |
| N | 55 | 56 | 58 | 56 |
| GMT* | 7.18 | 9.75 | 9.14 | 6.21 |
| Range | (0.9 to 29.5) | (0.9 to 153.1) | (1.2 to 228.9) | (0.9 to 81.9) |
| 95% CI | (5.63 to 9.15) | (7.46 to 12.76) | (6.86 to 12.20) | (4.86 to 7.95) |
| 1 year | | | | |
| N | 44 | 50 | 55 | 53 |
| GMT* | 2.52 | 3.21 | 4.60 | 1.33 |
| Range | (0.35 to 58.34) | (0.36 to 31.71) | (0.62 to 295.17) | (0.10 to 6.32) |
| 95% CI | (1.79 to 3.55) | (2.38 to 4.34) | (3.31 to 6.42) | (1.05 to 1.69) |

*IU/ml.
doi:10.1371/journal.pntd.0000224.t005




Figure 2. Rabies neutralising antibody results by the rabies fluorescent focus inhibition test (RFFIT). Symbols represent: ● Group A 4-site; ▲ Group B 8-site; x Group D 2-site; □ Group E intramuscular (IM). Points are geometric mean titres with 95% confidence intervals. doi:10.1371/journal.pntd.0000224.g002

This comparison showed general consistency but considerable individual variation, as demonstrated graphically in a Bland-Altman plot (Figure 5). Further analysis was not appropriate in such a small sample. All the FAVN results were <6 IU/ml, except one of 13.5 IU/ml (the RFFIT result was 2.8 IU/ml). For the RFFIT, all

titres were <7 IU/ml, except two of 8.39 and 9.36 IU/ml (the FAVN results were 1.14 and 3.42 IU/ml respectively).

The day 0 sera with RFFIT results >0.3 IU/ml, and day 14 sera with RFFIT results >3000 IU/ml, were included in a group of 38 otherwise randomly selected sera to be tested by the FAVN method.




Figure 3. Day 14 rabies fluorescent focus inhibition test (RFFIT) results antibody levels ≥ 0.5 IU/ml: difference in proportion between the geometric mean titres (GMTs) of any two regimens. Group A = 4-site intradermal (ID); Group B = 8-site ID; Group D = 2-site ID; Group E = intramuscular. doi:10.1371/journal.pntd.0000224.g003

Table 6. FAVN Serology Results for Day 7.

| | Group A 4-site | Group B 8-site | Group D 2-site | Group E IM |
|--------|----------------|----------------|----------------|----------------|
| N | 54 | 57 | 58 | 55 |
| GMT* | 0.673 | 0.907 | 1.044 | 0.573 |
| Range | (0.13 to 4.50) | (0.10 to 5.92) | (0.10 to 5.92) | (0.06 to 13.5) |
| 95% CI | (0.52 to 0.87) | (0.70 to 1.18) | (0.82 to 1.32) | (0.42 to 0.78) |

*IU/ml.

doi:10.1371/journal.pntd.0000224.t006

The day 0 results of 0.38 and 0.46 IU/ml were both 0.06 IU/ml by the FAVN. RFFIT results of 3711.5 and 3021.5 IU/ml were 53.3 and 121.2 IU/ml respectively by the FAVN.

Discussion

Interpretation

This study demonstrates that ID rabies vaccination is at least as immunogenic as the standard IM regimen and induces greater persistent immunity. ID regimens are therefore recommended anywhere in the world where the cost of PEP is critical. All three ID regimens required the same total amount of vaccine and proved equally immunogenic, but the 4-site ID regimen has several key advantages.

Advantages over the 2-site regimen

First, the 4-site needs one less clinic visit (omitting day 3). WHO now recommends omitting the day 90 dose of ID regimens, and doubling the day 28 dose [24,25,26]. The 4-site regimen would then require only 3 visits (days 0, 7 and 28) the same as the current 3 dose IM **pre**-exposure regimen, but using only about half the amount of vaccine.

Secondly, the 4-site regimen is safer than the 2-site as it uses a whole ampoule of vaccine divided between intradermal sites on the crucial first day. If some vaccine were inadvertently injected

subcutaneously, the wide margin of safety would ensure an adequate immune response [27]. Thirdly, sharing of ampoules of vaccine between patients is only necessary on days 7 and 28. The 4-site regimen can therefore be started in a rural clinic with referral a week later. It is economical anywhere if two or more people are treated on the same day.

Advantages over the 8-site method

The 4-site regimen can be used economically with current vaccines formulated in 0.5 and 1.0 ml ampoule sizes. Our results show that there is no need to divide the initial dose between 8 sites, because it was equally immunogenic in 4 sites. We injected over the deltoid and thigh areas, whereas Ambrozaitis et al. [16] used deltoid and suprascapular sites. The choice might be important in cultures where there is reluctance to expose the thighs.

Suppression of immune response by concomitant RIG treatment

The efficacy of the 8-site regimen has been demonstrated in patients bitten by proved rabid animals, with and without concomitant RIG [6]. Since the 4-site method has the same timing of doses and amount of vaccine, and is equally immunogenic, it can be inferred that RIG treatment would not be significantly immunosuppressive. All authorities recommend the combination of RIG with vaccine for PEP, especially




Figure 4. Rabies fluorescent focus inhibition test (RFFIT) results of the day 7 sera plotted with the results of the same sera tested by the fluorescent antibody virus neutralisation (FAVN) method. Symbols represent: ● Group A 4-site; ▲ Group B 8-site; x Group D 2-site; □ Group E IM. Points are geometric mean titres with 95% confidence intervals.

doi:10.1371/journal.pntd.0000224.g004




Figure 5. Bland-Altman plot of the difference between log RFFIT and log FAVN results, and the mean of the two values. Dotted lines are the 95% agreement limit. RFFIT = rabies fluorescent focus inhibition test, FAVN = fluorescent antibody virus neutralisation. doi:10.1371/journal.pntd.0000224.g005

for high risk exposure to rabies. Treatment failures are inevitable in severe cases (bites on the head, neck or hands or multiple bites) if vaccine is given alone. However RIG is not generally available or affordable in developing countries where it is given to <1% of PEP patients for whom it is recommended [28]. The 4-site regimen fulfils WHO requirements for immunogenicity for PEP and so could be introduced without further studies.

ID doses

WHO recommendations have changed since 1997, when the difference in dilution was recognised [15], to the latest rule that an ID dose of either vaccine is 0.1 ml [5,26]. Other studies of 8-site PVRV have used 0.1 ml per ID site [29], as recommended by WHO [5], which almost doubles the amount of vaccine used. The results for the 2-site regimen we report here apply to PVRV, the equivalent dose for PCECV would be 0.2 ml per site.

Ambrozaitis et al. [16] have tested this 4-site regimen to compare different doses of vaccine. Using PCECV, which is formulated in 1 ml ampoule, they showed that 0.1 ml per ID site, a lower dose, was as immunogenic as 0.1 ml per ID site of PVRV. This confirms the safety of our 4-site method, in which 0.25 ml of PCECV would be injected at each ID site on day 0, and 0.2 ml per site subsequently. Using the lower dose of 0.1 ml per site would sacrifice the advantages of using a whole ampoule on the first day, but would be more economical in large treatment centres [13].

Serological testing

The FAVN and the RFFIT tests are identical in principle but differ in the way their results are read. A comparison between these tests, performed within the same laboratory, showed close correlation [20], but there has been no report of inter-laboratory comparisons. Our data were too few for substantial analysis. In this study, at least one unusually high level was seen with one test, but not confirmed by the other. These results were used in the

analysis but did not affect the overall findings or conclusion. Similarly high individual results have been reported previously, but not explained [30,31,32]. Rabies immunisation is expensive and unusual in the UK. Thorough investigations excluded previous immunisation in the group analysed and so the high titres cannot be dismissed as an anamnestic response.

Antibody GMTs on days 7 and 14 were much higher, both by the RFFIT and FAVN than in some other recent studies [16,30]. Over 30 years, no difference has been reported in serological responses to tissue culture rabies vaccines between people in America, Europe and Asia. The higher levels found here remain unexplained. In a 2-site ID vaccine trial in Thailand, antibody levels varied 2.2 fold between different hospitals [30].

Conclusion

Economical rabies PEP regimens using 2, 4 or 8 initial ID sites are as immunogenic as the standard IM regimen, but they use 60% less vaccine. The 4-site regimen has several practical advantages over both currently used regimens, and is the most economical since only 3 or 4 clinic visits are needed (on days 0, 7 and 28 with optional day 90). Our finding that ID regimens were at least as immunogenic as the “gold standard” 5 dose IM regimen should increase confidence in multiple-site ID techniques. The 4-site regimen is suitable for use anywhere in the world where there are financial constraints, and especially where 2 or more patients are likely to be treated on the same day.

Supporting Information

Checklist S1

Found at: doi:10.1371/journal.pntd.0000224.s001 (0.06 MB DOC)

Protocol S1

Found at: doi:10.1371/journal.pntd.0000224.s002 (0.08 MB DOC)

Acknowledgments

We thank Sanofi Pasteur for their generous donation of the vaccine. We are grateful to other members of the Oxford Vaccine Group especially to: S. Segal and T. Chantler for their clinical support; to C. Banner and S. Lewis for technical assistance, and to T. Goddard for carrying out the FAVN tests. We thank the staff in the veterinary and medical departments of Bristol University for their help. The co-operation of the University of Oxford staff in many Departments and Colleges, and the prolonged enthusiasm of the volunteers is much appreciated.

References

- Knobel DL, Cleaveland S, Coleman PG, Fèvre EM, Meltzer MI, et al. (2005) Re-evaluating the burden of rabies in Africa and Asia. *Bull World Health Organ* 83: 360–8.
- Meslin F-X (2007) Rabies in Asia: Current scene and WHO's role in control. In: Conference Proceedings of RIACON-2007 First Conference of Rabies in Asia (RIA) Foundation. Bangalore, India. 3–4th March: 2.
- Mallewa M, Fooks AR, Banda D, Chikungwa P, Mankhambo L, et al. (2007) Rabies encephalitis in malaria-endemic area, Malawi, Africa. *Emerg Infect Dis* 13: 136–9.
- Dodet B (2006) Preventing the incurable: Asian rabies experts advocate rabies control. *Vaccine* 24: 3045–9.
- World Health Organization Expert Consultation on rabies. WHO Technical Report Series 931 First Report. WHO, (2006). Available: <http://www.wpro.who.int/NR/rdonlyres/B1ED8443-0993-408C-BF09-D1D06A6E1B45/0/FINALTEXTWHOTechnicalReportSeries090605.pdf> Accessed 25 February 2008.
- Warrell MJ, Nicholson KG, Warrell DA, Suntharasamai P, Chanthavanich P, et al. (1985) Economical multiple-site intradermal immunisation with human diploid-cell-strain vaccine is effective for post-exposure rabies prophylaxis. *Lancet* i: 1059–62.
- Chutivongse S, Wilde H, Supich C, Baer GM, Fishbein DB (1990) Postexposure prophylaxis for rabies with antiserum and intradermal vaccination. *Lancet* 335: 896–8.
- Strady C, Jaussaud R, Beguinot I, Lienard M, Strady A (2000) Predictive factors for the neutralizing antibody response following pre-exposure rabies immunization: validation of a new booster dose strategy. *Vaccine* 18: 2661–7.
- Jaijaroensup W, Tantawichien T, Khawplod P, Tepsumethanon S, Wilde H (1999) Postexposure rabies vaccination in patients infected with human immunodeficiency virus. *Clin Infect Dis* 28: 913–4.
- Deshpande A, Briggs DJ, Branzhoff A (2000) Investigation of immune responses to purified chick embryo cell tissue culture rabies vaccine (PCECV) in HIV infected individuals using a simulated post-exposure regimen. In: Proceedings of XIII International AIDS conference. Durban, South Africa. July 9–14. pp 163–8.
- Tantawichien T, Jaijaroensup W, Khawplod P, Sitprija V (2001) Failure of multiple-site intradermal postexposure rabies vaccination in patients with human immunodeficiency virus with low CD4+ T lymphocyte counts. *Clin Infect Dis* 33: E122–4.
- Thisyakorn U, Pancharoen C, Ruxrungham K, Ubolyam S, Khawplod P, et al. (2000) Safety and immunogenicity of preexposure rabies vaccination in children infected with human immunodeficiency virus type 1. *Clin Infect Dis* 30: 218.
- Goswami A, Plun-Favreau J, Nicoloyannis N, Sampath G, Siddiqui MN, et al. (2005) The real cost of rabies post-exposure treatments. *Vaccine* 23: 2970–6.
- Warrell MJ (2003) The challenge to provide affordable rabies post-exposure treatment. *Vaccine* 21: 706–9.
- World Health Organization (1997) WHO Recommendations on rabies post-exposure treatment and the correct technique of intradermal immunization against rabies. WHO/EMC/ZOO.96.6. WHO, 1997. Available: http://whqlibdoc.who.int/hq/1996/WHO_EMC_ZOO_96.6.pdf Accessed 25 February 2008.
- Ambrozaitis A, Laiskonis A, Balciuniene L, Banzhoff A, Malerczyk C (2006) Rabies post-exposure prophylaxis vaccination with purified chick embryo cell

Author Contributions

Wrote the paper: MJW. Supervised and co-ordinated the project: RM DAW. Conceived the project: MJW DAW. Contributed to the design, acquisition, and analysis of data: HB ARF. Performed and interpreted the statistical analysis: L-MY JJD. Contributed to the design and conduct of the study: MJW AR JP LD JJD AJP. Critically reviewed the manuscript: L-MY LD HB JJD ARF SMB RM AJP DAW. All authors approved the final article. Reviewed the protocol on behalf of the WHO: F-XM. Analysed and interpreted the serology: LA SMB.

- vaccine (PCECV) and purified Vero cell rabies vaccine (PVRV) in a four-site intradermal schedule (4-0-2-0-1-1): an immunogenic, cost-effective and practical regimen. *Vaccine* 24: 4116–21.
- Pappaioanou M, Fishbein DB, Dreesen DW, Schwartz IK, Campbell GH, et al. (1986) Antibody response to preexposure human diploid-cell rabies vaccine given concurrently with chloroquine. *N Engl J Med* 314: 280–4.
- Bourhy H, Sureau P (1990) Laboratory methods for rabies diagnosis. Paris: Institut Pasteur. pp 191–3.
- Feyssaguet M, Dacheux L, Audry L, Compoint A, Morize JL, et al. (2007) Multicenter comparative study of a new ELISA, PLATELIA RABIES II, for the detection and titration of anti-rabies glycoprotein antibodies and comparison with the rapid fluorescent focus inhibition test (RFFIT) on human samples from vaccinated and non-vaccinated people. *Vaccine* 25: 2244–51.
- Cliquet F, Aubert M, Sagne L (1998) Development of a fluorescent antibody virus neutralisation test (FAVN test) for the quantitation of rabies-neutralising antibody. *J Immunol Methods* 212: 79–87.
- OIE Manual of Diagnostic Tests and Vaccines for Terrestrial Animals 5th Edition (2004) Chapter 2.2.5. Rabies. OIE, Available: http://www.oie.int/Eng/Normes/Mmanual/A_00044.htm Accessed 25 February 2008.
- Newcombe RG (1998) Interval estimation for the difference between independent proportions: comparison of eleven methods. *Stat Med* 17: 873–90.
- Bland JM, Altman DG (1995) Comparing methods of measurement: why plotting difference against standard method is misleading. *Lancet* 346: 1085–7.
- Khawplod P, Tantawichien T, Wilde H, Limusanno S, Saikasem A, et al. (2002) Use of rabies vaccines after reconstitution and storage. *Clin Infect Dis* 34: 404–6.
- Khawplod P, Wilde H, Sirikwin S, Benjawongkulchai M, Limusanno S, et al. (2006) Revision of the Thai Red Cross intradermal rabies post-exposure regimen by eliminating the 90-day booster injection. *Vaccine* 24: 3084–6.
- World Health Organization (2007) Rabies vaccines. WHO position paper. *Wkly Epidemiol Rec* 82: 425–435. Available: http://www.who.int/wer/2007/wer8249_50.pdf Accessed 25 February 2008.
- Suntharasamai P, Warrell MJ, Viravan C, Chanthavanich P, Looareesuwan S, et al. (1987) Purified chick embryo cell rabies vaccine: economical multisite intradermal regimen for post-exposure prophylaxis. *Epidemiol Infect* 99: 755–65.
- Meslin FX (2005) Rabies as a traveler's risk, especially in high-endemicity areas. *J Travel Med* 12 Suppl 1: S30–40.
- Khawplod P, Wilde H, Tepsumethanon S, Limusanno S, Tantawichien T, et al. (2002) Prospective immunogenicity study of multiple intradermal injections of rabies vaccine in an effort to obtain an early immune response without the use of immunoglobulin. *Clin Infect Dis* 35: 1562–5.
- Briggs DJ, Banzhoff A, Nicolay U, Sirikwin S, Dumavibhat B, et al. (2000) Antibody response of patients after postexposure rabies vaccination with small intradermal doses of purified chick embryo cell vaccine or purified Vero cell rabies vaccine. *Bull World Health Organ* 78: 693–8.
- Moore SM, Rieke TA, Davis RD, Briggs DJ (2005) The influence of homologous vs. heterologous challenge virus strains on the serological test results of rabies virus neutralizing assays. *Biologicals* 33: 269–76.
- Suntharasamai P, Chanthavanich P, Supanaranond W, Warrell MJ (1988) One year booster vaccination with purified vero cell rabies vaccine. *Trans R Soc Trop Med Hyg* 82: 633.